VITAMIN K1

Post-LOE

phytonadione

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Jul 1983

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

VITAMIN K1 (phytonadione) by Pfizer is clinical pharmacology phytonadione injectable emulsion, aqueous dispersion of phytonadione for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin k, which is necessary for the production via the liver of active prothrombin (factor ii), proconvertin (factor vii), plasma thromboplastin component (factor ix), and stuart factor (factor x). Approved for the following coagulation disorders which are due to faulty formation of factors ii, interference with vitamin k activity, ulcerative colitis. First approved in 1983.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Phytonadione Injectable Emulsion, aqueous dispersion of Phytonadione for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II),…

Pharmacologic Class:

Vitamin K

Indications (3)

Worked on VITAMIN K1 at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.